#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Dementia Alzheimer's type Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Progressive multifocal leukoencephalopathy Choroid melanoma Mitochondrial DNA depletion Haemophilia B without inhibitors Angiosarcoma recurrent Cutaneous T-cell lymphoma refractory Chronic lymphocytic leukaemia Ornithine transcarbamoylase deficiency Acute leukaemia Glomerulonephritis membranoproliferative Spinal muscular atrophy Vulval cancer recurrent Leber's congenital amaurosis Acute myeloid leukaemia Desmoid tumour More trials…

    Learn about Rare Diseases

    Haemophilia A without inhibitors – Trials in Disease Cystic fibrosis – Trials in Disease Hereditary motor and sensory neuropathy – Trials in Disease Tuberous sclerosis complex – Diagnostics Methylmalonic acidaemia – Treatment Angiosarcoma recurrent Medulloblastoma Angelman’s syndrome Retinitis pigmentosa – Basic Information Turner’s syndrome – Diagnostics More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Erythromycin Beclometasone Dipropionate Isaralgagene Civaparvovec Cimetidine Remifentanil Hydrochloride Pyridoxine Hydrochloride Cilgavimab Lomustine VG801-1 Rp1 Tramazoline Hydrochloride Human Apotransferrin Human Serum Albumin Ranibizumab PROMESTRIENE Doxazosin Mesilate F1245/05 LTI-03 Rmc-035 Demeclocycline Hydrochloride More therapies…

    Learn about Your Condition

    Generalised anxiety disorder Thymic carcinoma Small intestine leiomyosarcoma Ureteric cancer Ophthalmoplegia Aneurysm ruptured Cardiac failure acute Malignant glioma Hodgkin's disease Arterial disorder Osteosarcoma metastatic Urinary tract infection Colorectal adenoma Pigmentary glaucoma Inner ear disorder More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Neoplasm malignant

  • Study of Lurbinectedin and Irinotecan for Patients with Advanced Solid Tumors

    Not recruiting

    1 1 1 1
    Investigated Drugs:
    • Lurbinectedin
    • Irinotecan
    France Italy Spain

  • Study of JDQ443, TNO155, and Tislelizumab for Patients with Advanced Solid Tumors with KRAS G12C Mutation

    Not recruiting

    2 1 1
    Investigated Drugs:
    • 1-{6-[(4M)-4-(5-Chloro-6-Methyl-1H -Indazol-4-Yl)-5-Methyl-3-(1-Methyl-1H -Indazol-5-Yl)-1H -Pyrazol-1-Yl]-2-Azaspiro[3.3]Heptan-2-Yl}Prop-2-En-1-One
    • Batoprotafib
    • Tislelizumab
    Belgium Denmark France Germany Italy The Netherlands +1

  • Study of ACP-017 and Pembrolizumab for Patients with Advanced or Metastatic Cancer

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Neoplasm malignant
    • Neoplasm
    Investigated Drugs:
    • Acp-017
    • Pembrolizumab
    The Netherlands Spain

  • Study of Elraglusib Alone or with Chemotherapy for Patients with Refractory Blood Cancers or Solid Tumors

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Haematological malignancy
    • Neoplasm malignant
    Investigated Drugs:
    • Elraglusib
    • Gemcitabine
    • Paclitaxel Albumin-Bound
    Belgium France Portugal Spain

  • Study on Atezolizumab and Tiragolumab for Patients with Head and Neck Cancer, Metastatic Melanoma, and Other Advanced Solid Tumors

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Malignant melanoma
    • Neoplasm malignant
    • Squamous cell carcinoma of head and neck
    Investigated Drugs:
    • Atezolizumab
    • Tiragolumab
    The Netherlands

  • Study of Nivolumab and Entinostat for Children and Adolescents with High-Risk Refractory or Relapsed Malignant Disease

    Not recruiting

    1 1 1 1
    Investigated Diseases:
    • Neoplasm malignant
    Investigated Drugs:
    • Entinostat
    • Nivolumab
    Austria France Germany The Netherlands Sweden
Previous Page
1 … 11 12 13 14 15 … 21
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!